{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:40:49Z","timestamp":1781703649512,"version":"3.54.5"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T00:00:00Z","timestamp":1639526400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>Antithyroglobulin antibody (TgAb) is a potential tumour marker for detecting differentiated thyroid cancer (DTC) recurrence, but insufficient data have supported its clinical applications. Our study aimed to describe the changing trend of TgAb after surgery and identify the relationship between this trend and clinical outcomes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients and Methods<\/jats:title><jats:p>We reviewed the electronic records of 1,686 DTC patients who had undergone total thyroidectomy (TT) and radioactive iodine (<jats:sup>131<\/jats:sup>I) therapy at West China Hospital of Sichuan University from January 2015 to December 2017. Finally, 289 preoperative TgAb-positive DTC patients were included and divided into four subgroups depending on the clinical outcome: Group A (tumour free), Group B (uncertain), Group C (incomplete biochemical response), and Group D (structural disease). The patient demographics, tumour characteristics, operations, pathology reports, and all serological biomarkers were reviewed and compared, and the prognostic efficacy of TgAb was evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among all 1,686 patients, 393 (23.65%) were TgAb positive (&amp;gt;40 IU\/ml) preoperatively. The TgAb level in Group A decreased significantly after surgery and <jats:sup>131<\/jats:sup>I therapy and stabilised at a low level after 1\u20132 years of <jats:sup>131<\/jats:sup>I therapy. However, in the other three groups, the decrease in TgAb was not significant after treatment. Conversely, TgAb declined slowly and remained stable or increased. The variations in TgAb relative to the preoperative level of Group A were significantly larger than those of Groups B, C, and D at most time points of follow-up (p &amp;lt; 0.001). By receiver operating characteristic (ROC) analyses, the variations of TgAb &amp;gt; \u221277.9% at 6 months after <jats:sup>131<\/jats:sup>I therapy (area under the curve (AUC) = 0.862; p &amp;lt; 0.001) and TgAb &amp;gt; \u221288.6% at 2 years after <jats:sup>131<\/jats:sup>I therapy (AUC = 0.901; p &amp;lt; 0.001) had good prognostic efficacy in tumour-free survival. When the variation in TgAb &amp;gt; \u221288.6% at 2 years after <jats:sup>131<\/jats:sup>I therapy was incorporated as a variable in the American Thyroid Association (ATA) categories, both intermediate- and high-risk patients also had a significantly increased chance of being tumour free (from 75.68% to 93.88% and 42.0% to 82.61%, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>For preoperative TgAb-positive DTC patients, variations in TgAb &amp;gt; \u221277.9% at 6 months after <jats:sup>131<\/jats:sup>I therapy and TgAb &amp;gt; \u221288.6% at 2 years after <jats:sup>131<\/jats:sup>I therapy had good prognostic efficacy. Their incorporation as variables in the ATA risk stratification system could more accurately predict disease-free survival.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fendo.2021.774275","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T08:53:54Z","timestamp":1639558434000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Antithyroglobulin Antibody Variation During Follow-Up Has a Good Prognostic Value for Preoperative Antithyroglobulin Antibody-Positive Differentiated Thyroid Cancer Patients: A Retrospective Study in Southwest China"],"prefix":"10.3389","volume":"12","author":[{"given":"Qianhui","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guixing","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30360","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: What Is New and What Has Changed","volume":"123","author":"Haugen","year":"2017","journal-title":"J Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients With Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"J Thyroid: Off J Am Thyroid Assoc"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.2002.01592.x","article-title":"Clinical Significance of Elevated Level of Serum Antithyroglobulin Antibody in Patients With Differentiated Thyroid Cancer After Thyroid Ablation","volume":"57","author":"Chung","year":"2002","journal-title":"J Clin Endocrinol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1089\/1050725041517057","article-title":"Why Measure Thyroglobulin Autoantibodies Rather Than Thyroid Peroxidase Autoantibodies","volume":"14","author":"McLachlan","year":"2004","journal-title":"J Thyroid: Off J Am Thyroid Assoc"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1053\/clon.1999.9056","article-title":"Thyroglobulin Antibodies in Differentiated Thyroid Cancer","volume":"11","author":"Hjiyiannakis","year":"1999","journal-title":"Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-21-0012","article-title":"Follow-Up of Patients With Thyroid Cancer and Antithyroglobulin Antibodies: A Review for Clinicians","volume":"28","author":"Weslley","year":"2021","journal-title":"J Endocr-Relat Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1967","article-title":"Thyroglobulin (Tg) Testing Revisited: Tg Assays, Tgab Assays, and Correlation of Results With Clinical Outcomes","volume":"100","author":"Netzel","year":"2015","journal-title":"J J Clin Endocrinol Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1089\/thy.2016.0210","article-title":"Thyroglobulin Liquid Chromatography-Tandem Mass Spectrometry Has a Low Sensitivity for Detecting Structural Disease in Patients With Antithyroglobulin Antibodies","volume":"27","author":"Azmat","year":"2017","journal-title":"J Thyroid: Off J Am Thyroid Assoc"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-020-02526-8","article-title":"The Role of a New Polyclonal Competitive Thyroglobulin Assay in the Follow-Up of Patients With Differentiated Thyroid Cancer With Structural Disease But Low Levels of Serum Thyroglobulin by Immunometric and LC-MS\/MS Methods","volume":"72","author":"Guastapaglia","year":"2020","journal-title":"J Endocrine"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2012.0606","article-title":"Implications of Thyroglobulin Antibody Positivity in Patients With Differentiated Thyroid Cancer: A Clinical Position Statement","volume":"23","author":"Verburg","year":"2013","journal-title":"J Thyroid: Off J Am Thyroid Assoc"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2015.0445","article-title":"Comparison of Antithyroglobulin Antibody Concentrations Before and After Ablation With 131I as a Predictor of Structural Disease in Differentiated Thyroid Carcinoma Patients With Undetectable Basal Thyroglobulin and Negative Neck Ultrasonography","volume":"26","author":"Rosario","year":"2016","journal-title":"J Thyroid: Off J Am Thyroid Assoc"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0962","article-title":"Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients With Differentiated Thyroid Carcinoma","volume":"93","author":"Kim","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.4158\/EP-2018-0436","article-title":"Prognosis of High-Risk Papillary Thyroid Cancer Patients With Pre-Ablation Stimulated Tg <1 Ng\/Ml","volume":"25","author":"Tian","year":"2019","journal-title":"J Endocrine Pract: Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0195","article-title":"Clinical Applicability of Low Levels of Thyroglobulin Autoantibodies as Cutoff Point for Thyroglobulin Autoantibody Positivity","volume":"29","author":"Dekker","year":"2019","journal-title":"J Thyroid: Off J Am Thyroid Assoc"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1515\/cclm-2017-0033","article-title":"Thyroglobulin Autoantibodies Before Radioiodine Ablation Predict Differentiated Thyroid Cancer Outcome","volume":"55","author":"Trimboli","year":"2017","journal-title":"Clin Chem Lab Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/CCO.0000000000000149","article-title":"Thyroglobulin Antibody Status and Differentiated Thyroid Cancer: What Does It Mean for Prognosis and Surveillance","volume":"27","author":"Gianoukakis","year":"2015","journal-title":"Curr Opin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-016-0578-6","article-title":"Relationship Between Circulating Anti-Thyroglobulin Antibodies (Tgab) and Tumor Metabolism in Patients With Differentiated Thyroid Cancer (DTC): Prognostic Implications","volume":"40","author":"Morbelli","year":"2017","journal-title":"J Endocrinol Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0080","article-title":"Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without I-131 Ablation","volume":"28","author":"Matrone","year":"2018","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.20945\/2359-3997000000123","article-title":"In Properly Selected Patients With Differentiated Thyroid Cancer, Antithyroglobulin Antibodies Decline After Thyroidectomy and Their Sole Presence Should Not Be an Indication for Radioiodine Ablation","volume":"63","author":"Zavala","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2009.03693.x","article-title":"Recurrence Detection in Differentiated Thyroid Cancer Patients With Elevated Serum Level of Antithyroglobulin Antibody: Special Emphasis on Using 18f-FDG PET\/Ct","volume":"72","author":"Seo","year":"2010","journal-title":"Clin Endocrinol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1155\/2020\/8312628","article-title":"Prognostic Significance of Thyroglobulin Antibodies in Differentiated Thyroid Cancer","volume":"2020","author":"Reverter","year":"2020","journal-title":"J Thyroid Res"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0903","article-title":"The Association Between Papillary Thyroid Carcinoma and Histologically Proven Hashimoto\u2019s Thyroiditis: A Meta-Analysis","volume":"168","author":"Ju-Han","year":"2013","journal-title":"J Eur J Endocrinol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2019.0368","article-title":"Investigating Antithyroglobulin Antibody as a Prognostic Marker for Differentiated Thyroid Cancer: A Meta-Analysis and Systematic Review","volume":"30","author":"Lee","year":"2020","journal-title":"Thyroid"},{"key":"B24","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1089\/thy.1994.4.199","article-title":"Significance of Antithyroglobulin Autoantibodies in Differentiated Thyroid Carcinoma","volume":"4","author":"Kumar","year":"1994","journal-title":"J Thyroid: Off J Am Thyroid Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2217\/bmm-2019-0432","article-title":"Prognostic Value and Dynamics of Antithyroglobulin Antibodies for Differentiated Thyroid Carcinoma","volume":"14","author":"Danyang","year":"2020","journal-title":"J Biomarkers Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2017.05.028","article-title":"Back So Soon? Is Early Recurrence of Papillary Thyroid Cancer Really Just Persistent Disease","volume":"163","author":"Bates","year":"2018","journal-title":"J Surg"}],"updated-by":[{"DOI":"10.3389\/fendo.2022.899184","type":"corrigendum","label":"Corrigendum","source":"publisher","updated":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000}}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.774275\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T15:41:24Z","timestamp":1651074084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.774275\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,15]]},"references-count":26,"alternative-id":["10.3389\/fendo.2021.774275"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2021.774275","relation":{"corrigendum":[{"id-type":"doi","id":"10.3389\/fendo.2022.899184","asserted-by":"object"}]},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,15]]},"article-number":"774275"}}